News | April 15, 2025
Biocon Biologics secures market entry date for Yesafili in US
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
Strengthening capabilities in Peptide Therapeutics and CDMO services
Pregabalin Gel 8% is a novel topical solution for diabetic neuropathic pain
There are 38.4 million people with diabetes in the United States
In financial year 2024-25, PMBJP has made sales of Rs. 1,760 crore (at MRP) till Feb 2025
Among those identified, 2.4 lakh patients have been notified from public health institutions, while 1.1 lakh were identified through private healthcare facilities
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME)
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
He is an experienced professional in the pharmaceutical industry with about 30 years of progressive experience
Subscribe To Our Newsletter & Stay Updated
